Safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome

Pediatric Research

Volumn 58, Issue 1, 2005, Pages 15-21

  Levine, Carolyn R ^a   Gewolb, Ira H ^c   Allen, Kristen ^a   Welch, Richard W ^e   Melby, James M ^e   Pollack, Simcha ^a,b   Shaffer, Thomas ^d   Pilon, Aprile L ^e   Davis, Jonathan M ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Claragen Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CC 10; CLARA CELL PROTEIN; OXYGEN; PROTEIN; SURFACTANT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; INFANT; LUNG DYSPLASIA; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NEUTROPHIL; OXYGEN THERAPY; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BIRTH WEIGHT; BRONCHOPULMONARY DYSPLASIA; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFLAMMATION; LUNG; MALE; OXYGEN; PLACEBOS; RANDOM ALLOCATION; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SAFETY; TIME FACTORS; TRACHEA; TREATMENT OUTCOME; UTEROGLOBIN;

EID: 22044452785     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000156371.89952.35     Document Type: Article

References (29)

1. Mukherjee AB, Kundu GC, Mantile-Selvaggi G, Yuan CJ, Mandal AK, Chattopadhyay S, Zheng F, Pattabiraman N, Zhang Z 1999 Uteroglobin: a novel cytokine? Cell Mol Life Sci 55:771-787
2. Singh G, Singal S, Katyal SL, Brown WE, Gottron SA 1987 Isolation and amino acid composition of the isotypes of a rat Clara cell specific protein. Exp Lung Res 13:299-309
3. Peri A, Cordella-Miele E, Miele L, Mukherjee AB 1993 Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitory protein. J Clin Invest 92:2099-2109
4. Rauch M, Loosfelt H, Philibert D, Milgrom E 1985 Mechanism of action of an antiprogesterone, RU486, in the rabbit endometrium. Effects of RU486 on the progesterone receptor and on the expression of the uteroglobin gene. Eur J Biochem 148:213-218
5. Kikukawa T, Mukherjee AB 1989 Detection of a uteroglobin-like phospholipase A2 inhibitory protein in the circulation of rabbits. Mol Cell Endocrinol 62:177-187
6. Bernard A, Roels H, Lauwerys R, Witters R, Gielens C, Soumillion A, Van Damme J, De Ley M 1992 Human urinary protein 1: evidence for identity with the Clara cell protein and occurrence in respiratory tract and urogenital secretions. Clin Chim Acta 207:239-249
7. Levin SW, Butler JD, Schumacher UK, Wightman PD, Mukherjee AB 1986 Uteroglobin inhibits phospholipase A2 activity. Life Sci 38:1813-1819
8. Mantile G, Miele L, Cordella-Miele E, Singh G, Katyal SL, Mukherjee AB 1993 Human Clara cell 10-kDa protein is the counterpart of rabbit uteroglobin. J Biol Chem 268:20343-20351
9. Vasanthakumar G, Manjunath R, Mukherjee AB, Warabi H, Schiffmann E 1988 Inhibition of phagocyte chemotaxis by uteroglobin, an inhibitor of blastocyst rejection. Biochem Pharmacol 37:389-394
10. Lesur O, Bernard A, Arsalane K, Lauwerys R, Begin R, Cantin A, Lane D 1995 Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med 152:290-297
11. Dierynck I, Bernard A, Roels H, De Ley M 1996 The human Clara cell protein: biochemical and biological characterisation of a natural immunosuppressor. Mult Scler 1:385-387
12. Zheng F, Kundu GC, Zhang Z, Ward J, DeMayo F, Mukherjee AB 1999 Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. Nat Med 5:1018-1025
13. Johnston CJ, Mango GW, Finkelstein JN, Stripp BR 1997 Altered pulmonary response to hyperoxia in Clara cell secretory protein deficient mice. Am J Respir Cell Mol Biol 17:147-155
14. Wang SZ, Rosenberger CL, Bao YX, Stark JM, Harrod KS 2003 Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. J Immunol 171:1051-1060
15. Dhanireddy R, Lim M, Mukherjee A 1993 Uteroglobin-like protein levels in premature infants on long term ventilatory support. Pediatr Res 33:323A
16. Bernard A, Thielemans N, Lauwerys R, Langhendries JP, Van Lierde M, Freund MM 1994 Clara cell protein in human amniotic fluid: a potential marker of fetal lung growth. Pediatr Res 36:771-775
17. Lassus P, Nevalainen TJ, Eskola JU, Andersson S 2000 Clara-cell secretory protein in preterm infants' tracheal aspirates correlates with maturity and increases in infection. Pediatr Pulmonol 30:466-469
18. Ramsay PL, DeMayo FJ, Hegemier SE, Wearden ME, Smith CV, Welty SE 2001 Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. Am J Respir Crit Care Med 164:155-161
19. Chandra S, Davis JM, Drexler S, Kowalewska J, Chester D, Koo HC, Pollack S, Welch R, Pilon A, Levine CR 2003 Safety and efficacy of intratracheal recombinant human Clara cell protein in a newborn piglet model of acute lung injury. Pediatr Res 54:509-515
20. Langenback EG, Davis JM, Robbins C, Sahgal N, Perry RJ, Simon SR 1999 Improved pulmonary distribution of recombinant human Cu/Zn Superoxide dismutase, using a modified ultrasonic nebulizer. Pediatr Pulmonol 27:124-129
21. Mantile G, Fuchs C, Cordella-Miele E, Peri A, Mukherjee AB, Miele L 2000 Stable, long-term bacterial production of soluble, dimeric, disulfide-bonded protein pharmaceuticals without antibiotic selection. Biotechnol Prog 16:17-25
22. Nordby-Shashikant B, Miller TL, Melby J, Pilon AL, Shatter TH, Wolfson MR 2003 Dose-response to rhCC10-augmented surfactant (SF) therapy in infant respiratory distress syndrome (RDS): inflammation and kinetic profiles. Pediatr Res 53:463A
23. Nordby-Shashikant B, Miller TL, Melby J, Pilon AL, Shaffer TH, Wolfson MR 1992 rhCC10-augmented surfactant (SF) therapy in acute lung injury (ALI): physiological and inflammatory profiles. Pediatr Res 51:469A
24. Bagchi A, Viscardi RM, Taciak V, Ensor JE, McCrea KA, Hasday JD 1994 Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res 36:244-252
25. Speer CP 2001 New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 79:205-209
26. Manjunath R, Levin SW, Kumaroo KK, Butler JD, Donlon JA, Home M, Fujita R, Schumacher UK, Mukherjee AB 1987 Inhibition of thrombin-induced platelet aggregation by uteroglobin. Biochem Pharmacol 36:741-746
27. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W; North American Recombinant Human CuZnSOD Study Group 2003 Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn Superoxide dismutase. Pediatrics 111:469-476
28. Barrington KJ 2001 The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 1:1
29. Yeh TF, Lin YJ, Huang CC, Chen JY, Lin CH, Lin HC, Hsieh WS, Lien YJ 1998 Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 101:E7